Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis

Maya H Buch; Josef S Smolen; Neil Betteridge; Ferdinand C Breedveld; Gerd Burmester; Thomas Dörner; Gianfranco Ferraccioli; Jacques-Eric Gottenberg; John Isaacs; Tore K Kvien; Xavier Mariette; Emilio Martin-Mola; Karel Pavelka; Paul P Tak; Desiree van der Heijde; Ronald F van Vollenhoven; Paul Emery; Rituximab Consensus Expert Committee; Mikkel Østergaard

doi:http://dx.doi.org/10.1136/ard.2010.144998

Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis

Maya H Buch, Josef S Smolen, Neil Betteridge, Ferdinand C Breedveld, Gerd Burmester, Thomas Dörner, Gianfranco Ferraccioli, Jacques-Eric Gottenberg, John Isaacs, Tore K Kvien, Xavier Mariette, Emilio Martin-Mola, Karel Pavelka, Paul P Tak, Desiree van der Heijde, Ronald F van Vollenhoven, Paul Emery, Rituximab Consensus Expert Committee, Mikkel Østergaard

281 Citations (Scopus)

Abstract

Background Since initial approval for the treatment of rheumatoid arthritis (RA), rituximab has been evaluated in clinical trials involving various populations with RA. Information has also been gathered from registries. This report therefore updates the 2007 consensus document on the use of rituximab in the treatment of RA. Methods Preparation of this new document involved many international experts experienced in the treatment of RA. Following a meeting to agree upon the core agenda, a systematic literature review was undertaken to identify all relevant data. Data were then interrogated by a drafting committee, with subsequent review and discussion by a wider expert committee leading to the formulation of an updated consensus statement. These committees also included patients with RA. Results The new statement covers wide-ranging issues including the use of rituximab in earlier RA and impact on structural progression, and aspects particularly pertinent to rituximab such as co-medication, optimal dosage regimens, repeat treatment cycles and how to manage non-response. Biological therapy following rituximab usage is also addressed, and safety concerns including appropriate screening for hepatitis, immunoglobulin levels and infection risk. This consensus statement will support clinicians and inform patients when using B-cell depletion in the management of RA, providing up-to-date information and highlighting areas for further research. Conclusion New therapeutic strategies and treatment options for RA, a chronic destructive and disabling disease, have expanded over recent years. These have been summarised in general strategic suggestions and specific management recommendations, emphasising the importance of expedient disease-modifying antirheumatic drug implementation and tight disease control. This consensus statement is in line with these fundamental principles of management.

Original language	English
Journal	Annals of the Rheumatic Diseases
Volume	70
Issue number	6
Pages (from-to)	909-20
Number of pages	12
ISSN	0003-4967
DOIs	https://doi.org/10.1136/ard.2010.144998
Publication status	Published - Jun 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

http://dx.doi.org/10.1136/ard.2010.144998

Cite this

Buch, M. H., Smolen, J. S., Betteridge, N., Breedveld, F. C., Burmester, G., Dörner, T., Ferraccioli, G., Gottenberg, J-E., Isaacs, J., Kvien, T. K., Mariette, X., Martin-Mola, E., Pavelka, K., Tak, P. P., van der Heijde, D., van Vollenhoven, R. F., Emery, P., Rituximab Consensus Expert Committee, & Østergaard, M. (2011). Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 70(6), 909-20. https://doi.org/10.1136/ard.2010.144998

Buch, MH, Smolen, JS, Betteridge, N, Breedveld, FC, Burmester, G, Dörner, T, Ferraccioli, G, Gottenberg, J-E, Isaacs, J, Kvien, TK, Mariette, X, Martin-Mola, E, Pavelka, K, Tak, PP, van der Heijde, D, van Vollenhoven, RF, Emery, P, Rituximab Consensus Expert Committee & Østergaard, M 2011, 'Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis', Annals of the Rheumatic Diseases, vol. 70, no. 6, pp. 909-20. https://doi.org/10.1136/ard.2010.144998

@article{66a6ab7e175347d5bfdaaab65bb3fc02,

title = "Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis",

abstract = "Background Since initial approval for the treatment of rheumatoid arthritis (RA), rituximab has been evaluated in clinical trials involving various populations with RA. Information has also been gathered from registries. This report therefore updates the 2007 consensus document on the use of rituximab in the treatment of RA. Methods Preparation of this new document involved many international experts experienced in the treatment of RA. Following a meeting to agree upon the core agenda, a systematic literature review was undertaken to identify all relevant data. Data were then interrogated by a drafting committee, with subsequent review and discussion by a wider expert committee leading to the formulation of an updated consensus statement. These committees also included patients with RA. Results The new statement covers wide-ranging issues including the use of rituximab in earlier RA and impact on structural progression, and aspects particularly pertinent to rituximab such as co-medication, optimal dosage regimens, repeat treatment cycles and how to manage non-response. Biological therapy following rituximab usage is also addressed, and safety concerns including appropriate screening for hepatitis, immunoglobulin levels and infection risk. This consensus statement will support clinicians and inform patients when using B-cell depletion in the management of RA, providing up-to-date information and highlighting areas for further research. Conclusion New therapeutic strategies and treatment options for RA, a chronic destructive and disabling disease, have expanded over recent years. These have been summarised in general strategic suggestions and specific management recommendations, emphasising the importance of expedient disease-modifying antirheumatic drug implementation and tight disease control. This consensus statement is in line with these fundamental principles of management.",

author = "Buch, {Maya H} and Smolen, {Josef S} and Neil Betteridge and Breedveld, {Ferdinand C} and Gerd Burmester and Thomas D{\"o}rner and Gianfranco Ferraccioli and Jacques-Eric Gottenberg and John Isaacs and Kvien, {Tore K} and Xavier Mariette and Emilio Martin-Mola and Karel Pavelka and Tak, {Paul P} and {van der Heijde}, Desiree and {van Vollenhoven}, {Ronald F} and Paul Emery and Mikkel {\O}stergaard and Mikkel {\O}stergaard",

note = "Mikkel {\O}stergaard er tilf{\o}jet denne publikation som medlem af Rituximab Consensus Expert Committee",

year = "2011",

month = jun,

doi = "http://dx.doi.org/10.1136/ard.2010.144998",

language = "English",

volume = "70",

pages = "909--20",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "B M J Group",

number = "6",

}

TY - JOUR

T1 - Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis

AU - Buch, Maya H

AU - Smolen, Josef S

AU - Betteridge, Neil

AU - Breedveld, Ferdinand C

AU - Burmester, Gerd

AU - Dörner, Thomas

AU - Ferraccioli, Gianfranco

AU - Gottenberg, Jacques-Eric

AU - Isaacs, John

AU - Kvien, Tore K

AU - Mariette, Xavier

AU - Martin-Mola, Emilio

AU - Pavelka, Karel

AU - Tak, Paul P

AU - van der Heijde, Desiree

AU - van Vollenhoven, Ronald F

AU - Emery, Paul

AU - Rituximab Consensus Expert Committee

AU - Østergaard, Mikkel

N1 - Mikkel Østergaard er tilføjet denne publikation som medlem af Rituximab Consensus Expert Committee

PY - 2011/6

Y1 - 2011/6

N2 - Background Since initial approval for the treatment of rheumatoid arthritis (RA), rituximab has been evaluated in clinical trials involving various populations with RA. Information has also been gathered from registries. This report therefore updates the 2007 consensus document on the use of rituximab in the treatment of RA. Methods Preparation of this new document involved many international experts experienced in the treatment of RA. Following a meeting to agree upon the core agenda, a systematic literature review was undertaken to identify all relevant data. Data were then interrogated by a drafting committee, with subsequent review and discussion by a wider expert committee leading to the formulation of an updated consensus statement. These committees also included patients with RA. Results The new statement covers wide-ranging issues including the use of rituximab in earlier RA and impact on structural progression, and aspects particularly pertinent to rituximab such as co-medication, optimal dosage regimens, repeat treatment cycles and how to manage non-response. Biological therapy following rituximab usage is also addressed, and safety concerns including appropriate screening for hepatitis, immunoglobulin levels and infection risk. This consensus statement will support clinicians and inform patients when using B-cell depletion in the management of RA, providing up-to-date information and highlighting areas for further research. Conclusion New therapeutic strategies and treatment options for RA, a chronic destructive and disabling disease, have expanded over recent years. These have been summarised in general strategic suggestions and specific management recommendations, emphasising the importance of expedient disease-modifying antirheumatic drug implementation and tight disease control. This consensus statement is in line with these fundamental principles of management.

AB - Background Since initial approval for the treatment of rheumatoid arthritis (RA), rituximab has been evaluated in clinical trials involving various populations with RA. Information has also been gathered from registries. This report therefore updates the 2007 consensus document on the use of rituximab in the treatment of RA. Methods Preparation of this new document involved many international experts experienced in the treatment of RA. Following a meeting to agree upon the core agenda, a systematic literature review was undertaken to identify all relevant data. Data were then interrogated by a drafting committee, with subsequent review and discussion by a wider expert committee leading to the formulation of an updated consensus statement. These committees also included patients with RA. Results The new statement covers wide-ranging issues including the use of rituximab in earlier RA and impact on structural progression, and aspects particularly pertinent to rituximab such as co-medication, optimal dosage regimens, repeat treatment cycles and how to manage non-response. Biological therapy following rituximab usage is also addressed, and safety concerns including appropriate screening for hepatitis, immunoglobulin levels and infection risk. This consensus statement will support clinicians and inform patients when using B-cell depletion in the management of RA, providing up-to-date information and highlighting areas for further research. Conclusion New therapeutic strategies and treatment options for RA, a chronic destructive and disabling disease, have expanded over recent years. These have been summarised in general strategic suggestions and specific management recommendations, emphasising the importance of expedient disease-modifying antirheumatic drug implementation and tight disease control. This consensus statement is in line with these fundamental principles of management.

U2 - http://dx.doi.org/10.1136/ard.2010.144998

DO - http://dx.doi.org/10.1136/ard.2010.144998

M3 - Journal article

SN - 0003-4967

VL - 70

SP - 909

EP - 920

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

IS - 6

ER -

Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this